Pharmaceutical

FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use

At BIO 2025, FDA Commissioner Dr Marty Makary tried to allay industry concerns about recent cuts and outlined his agenda for the future.

Jun 19, 2025 - 06:00
FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use
At BIO 2025, FDA Commissioner Dr Marty Makary tried to allay industry concerns about recent cuts and outlined his agenda for the future.
Read the original article

Tags:

Previous Article

Tisento’s MELAS treatment receives fast track status from FDA

Next Article

Navigating tariffs and diplomacy: the future of India-US pharmaceutical trade

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Ablaze Pharmaceuticals to develop drug candidate for liver cancer

Ablaze Pharmaceuticals to develop drug candidate for li...

Apr 3, 2023

Amgen sees highest patent filings and grants during July in Q3 2023

Amgen sees highest patent filings and grants during Jul...

Nov 24, 2023

Insmed’s gene therapy poised to challenge DMD landscape after IND clearance

Insmed’s gene therapy poised to challenge DMD landscape...

Jan 16, 2025